4 Comments

There's a small pharma company, Lexeo Therapeutics, that is already running a trial to flip APOE4/4 homozygous carriers to APOE4/2. Their treatment is called ALZ-801 and the trial is supposed to have some results this year. It would be great if you could interview them or write about it!

ALZ-801 trial info: https://www.alzheimers.gov/clinical-trials/alz-801-early-alzheimers-people-apoe4-4-genotype-apolloe4

NYTimes article on the study, from Dec 2022: https://www.nytimes.com/2022/12/02/health/alzheimers-apoe4-gene-therapy.html

This treatment is through cerebral spinal fluid, but I've also heard some speculation, and I'm sorry that I can't remember from where exactly, that even if you converted only APOE4s to APOE2s in the blood, and you don't get much penetration into the brain, that there are reasons to believe it could have a strong positive impact on preventing Alzheimer's.

Also would love your take on that new Alzheimer's prion paper.

Expand full comment
Mar 3·edited Mar 3Liked by Eric Topol

from a March 2022 Lexeo press release - “Initial data have shown meaningful APOE2 target engagement and declines in cerebrospinal fluid biomarkers, which support our belief that LX1001 has therapeutic potential for APOE4-associated Alzheimer’s disease,” said Jay A. Barth, M.D., Executive Vice President and Chief Medical Officer of LEXEO.

Expand full comment
founding
Mar 3Liked by Eric Topol

I'm so glad these days for our 'Weekend's with Eric' and his wonderful Ground Truths :-) It's like our brains are getting a turbo-charged kick-in-the-pants each week ... can hardly wait for the next fuel stop!

Expand full comment
author

thank you!!

Expand full comment